EcoDrugPlus

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSKMAG00000010170
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSKMAG00000018281
Gene Symbol: EML4
4 Cross references
192 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSKMAG00000000649
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSKMAG00000006724
Gene Symbol: F2RL3
4 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSKMAG00000019812
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSKMAG00000015877
Gene Symbol: FYN
4 Cross references
196 Possible Orthologues:

G-Protein Coupled Receptor 84-Like

Ensembl ID : ENSKMAG00000019042
Gene Symbol: LOC108235641
3 Cross references
113 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSKMAG00000017277
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSKMAG00000017005
Gene Symbol: ITK
3 Cross references
205 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSKMAG00000011718
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSKMAG00000003938
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSKMAG00000014799
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).